Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM)

被引：0
|
作者：
Kadowaki, Takashi
Tajima, Naoko
Odawara, Masato
Nishii, Mikio
Nonaka, Kenji
Stein, Peter P.
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A589 / A590
页数：2
相关论文
共 50 条
  • [21] Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control
    Tajima N.
    Kadowaki T.
    Odawara M.
    Nishii M.
    Taniguchi T.
    Ferreira J.C.A.
    Diabetology International, 2011, 2 (1) : 32 - 44
  • [22] Gemigliptin added to ongoing metformin therapy provides sustained glycaemic control over 52 weeks and was well tolerated in patients with type 2 diabetes
    Rhee, E. J.
    Min, K. W.
    Jang, H. C.
    Chung, C. H.
    Nam-Goong, I. S.
    Bae, H. Y.
    Baik, S. H.
    Shivane, V. K.
    Sosale, A. R.
    Dharmalingam, M.
    Gandhi, P.
    Gupta, S. K.
    Ahn, J. Y.
    Bang, K. S.
    Lee, M. K.
    DIABETOLOGIA, 2013, 56 : S52 - S52
  • [23] Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI)
    Scott, Russell
    Hartley, Paul
    Luo, Edmund
    Yee, Jacqueline
    Davies, Michael
    Ferreira, Juan Camilo Arjona
    Williams-Herman, Debora
    DIABETES, 2006, 55 : A462 - A462
  • [24] Adherence to Treatment Guidelines in Type 2 Diabetes (T2DM) Patients Treated with Metformin (MET) Monotherapy with Suboptimal Glycemic Control in Israeli Managed Care
    Goldshtein, Inbal
    Tunceli, Kaan
    Radican, Larry
    Katzeff, Harvey
    Yu, Shengsheng
    Voss, Bernd
    Sharon, Ofer
    Gadir, Noga
    Brodovicz, Kimberly
    Shalev, Varda
    Chodik, Gabriel
    Karasik, Avraham
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 111 - 111
  • [25] Hyperglycemia Drives Glycemic Variability in Patients with Type 2 Diabetes (T2DM)
    Olawsky, Evan A.
    Zhang, Yuan
    Alvear, Alison C.
    Eberly, Lynn E.
    Chow, Lisa S.
    DIABETES, 2020, 69
  • [26] Adherence to Treatment Guidelines in Type 2 Diabetes (T2DM) Patients Treated with Metformin (MET) Monotherapy with Suboptimal Glycemic Control in Israeli Managed Care
    Tunceli, Kaan
    Goldstein, Inbal
    Radican, Larry
    Katzeff, Harvey
    Yu, Shengsheng
    Voss, Bernd
    Sharon, Ofer
    Gadir, Noga
    Brodovicz, Kimberly
    Shalev, Varda
    Chodik, Gabriel
    Karasik, Avraham
    DIABETES, 2014, 63 : A304 - A304
  • [27] Personality, Self-Management Behaviors, and Glycemic Control among Japanese Patients with Type 2 Diabetes Mellitus (T2DM)
    Morikawa, Sakiko Y.
    Fujihara, Kazuya
    Hatta, Mariko
    Takeda, Yasunaga
    Ishii, Dai
    Yachida, Junko
    Horikawa, Chika
    Kato, Mitsutoshi
    Maegawa, Hiroshi
    Sone, Hirohito
    DIABETES, 2019, 68
  • [28] Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM)
    Aschner, Pablo
    Kipnes, Mark
    Lunceford, Jared
    Mickel, Carolyn
    Davies, Michael
    Williams-Herman, Debora
    DIABETES, 2006, 55 : A462 - A462
  • [29] Safety and Efficacy of Sitagliptin Added to the Combination of Sulfonylurea and Metformin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Round, Elizabeth
    Shentu, Yue
    Golm, Gregory T.
    O'Neill, Edward A.
    Gantz, Ira
    Engel, Samuel S.
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES, 2013, 62 : A299 - A299
  • [30] Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM)
    Rosenstock, Julio
    Brazg, Ronald
    Andryuk, Paula J.
    Sisk, Christine McCrary
    Lu, Kaifeng
    Stein, Peter
    DIABETES, 2006, 55 : A132 - A133
12345